Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Capital Employed (2020 - 2025)

Ovid Therapeutics' Return on Capital Employed history spans 6 years, with the latest figure at 0.43% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 28.0% year-over-year to 0.43%; the TTM value through Dec 2025 reached 0.43%, up 28.0%, while the annual FY2025 figure was 0.37%, 20.0% up from the prior year.
  • Return on Capital Employed reached 0.43% in Q4 2025 per OVID's latest filing, up from 0.64% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.82% in Q1 2021 to a low of 0.73% in Q1 2025.
  • Average Return on Capital Employed over 5 years is 0.25%, with a median of 0.44% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: soared 199bps in 2021, then tumbled -103bps in 2022.
  • A 5-year view of Return on Capital Employed shows it stood at 0.67% in 2021, then tumbled by -154bps to 0.36% in 2022, then crashed by -33bps to 0.48% in 2023, then crashed by -48bps to 0.71% in 2024, then skyrocketed by 40bps to 0.43% in 2025.
  • Per Business Quant, the three most recent readings for OVID's Return on Capital Employed are 0.43% (Q4 2025), 0.64% (Q3 2025), and 0.59% (Q2 2025).